Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma

ABSTRACT Introduction Pembrolizumab, a monoclonal antibody directed against the immune checkpoint programmed cell death‐1 receptor (PD‐1), has improved survival in patients with advanced melanoma. Neuromuscular immune‐mediated side effects have been rarely reported. Methods We describe a 44‐year‐old...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Muscle & nerve 2017-12, Vol.56 (6), p.E162-E167
Hauptverfasser:	Sepúlveda, Maria, Martinez‐Hernandez, Eugenia, Gaba, Lydia, Victoria, Ivan, Sola‐Valls, Nuria, Falgàs, Neus, Casanova‐Molla, Jordi, Graus, Francesc
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents, Immunological - adverse effects anti‐programmed death‐1 receptor Apoptosis Atrophy Cell death Cerebrospinal fluid Complications Drugs Fibrillation Humans Immune checkpoint immune neuropathy Immunosuppressive agents Immunotherapy Intravenous administration Limbs Magnetic resonance imaging Male Melanoma Melanoma - complications Melanoma - drug therapy Metastases Metastasis Monoclonal antibodies Muscle Weakness - chemically induced Muscle Weakness - complications Muscle Weakness - diagnostic imaging PD-1 protein pembrolizumab polyradiculoneuropathy Polyradiculopathy - chemically induced Polyradiculopathy - complications Polyradiculopathy - diagnostic imaging Side effects Skin Neoplasms - complications Skin Neoplasms - drug therapy Steroid hormones Steroids Targeted cancer therapy toxic neuropathy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!